Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: C.B. Fleet

This article was originally published in The Tan Sheet

Executive Summary

C.B. Fleet: FDA needs additional data before it will schedule a "feedback" meeting with the firm on its petition to include two 45 ml doses of dibasic sodium phosphate/monobasic sodium phosphate solution in sequential administration 10-12 hours apart as a bowel cleansing system in the OTC laxative monograph. The agency told Fleet in a July 3 letter that individual subject data for the two abstracts and one unpublished study submitted by the firm "would be required to better evaluate the safety issues related to this sequential bowel cleansing system." The firm filed the petition in March 1993...

Topics

UsernamePublicRestriction

Register

PS085877

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel